Cargando…

Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants

Aims: Patients after heart transplantation (HTX) often require oral anticoagulants (OACs) due to atrial arrhythmias or thromboembolic events but little is known about the post-transplant use of direct oral anticoagulants (DOACs). We investigated the frequency, indications, and complications of DOACs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darche, Fabrice F., Fabricius, Lisa C., Helmschrott, Matthias, Rahm, Ann-Kathrin, Ehlermann, Philipp, Bruckner, Tom, Sommer, Wiebke, Warnecke, Gregor, Frey, Norbert, Rivinius, Rasmus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342416/ https://www.ncbi.nlm.nih.gov/pubmed/37445369 http://dx.doi.org/10.3390/jcm12134334

Ejemplares similares

Frequency, Risk Factors, and Clinical Outcomes of Late-Onset Atrial Flutter in Patients after Heart Transplantation
por: Rahm, Ann-Kathrin, et al.
Publicado: (2022)

Newly acquired complete right bundle branch block early after heart transplantation is associated with lower survival
por: Rahm, Ann‐Kathrin, et al.
Publicado: (2021)

Atrial fibrillation before heart transplantation is a risk factor for post‐transplant atrial fibrillation and mortality
por: Darche, Fabrice F., et al.
Publicado: (2021)

Risk Factors, Treatment and Prognosis of Patients with Lung Cancer after Heart Transplantation
por: Heil, Karsten M., et al.
Publicado: (2021)

Pre-transplant Type 2 Diabetes Mellitus Is Associated With Higher Graft Failure and Increased 5-Year Mortality After Heart Transplantation
por: Rivinius, Rasmus, et al.
Publicado: (2022)

Correction to: Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation
por: Rivinius, Rasmus, et al.
Publicado: (2021)

Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation
por: Rivinius, Rasmus, et al.
Publicado: (2020)

Chronic digitalis therapy in patients before heart transplantation is an independent risk factor for increased posttransplant mortality
por: Rivinius, Rasmus, et al.
Publicado: (2017)

Combined amiodarone and digitalis therapy before heart transplantation is associated with increased post‐transplant mortality
por: Rivinius, Rasmus, et al.
Publicado: (2020)

COPD in patients after heart transplantation is associated with a prolonged hospital stay, early posttransplant atrial fibrillation, and impaired posttransplant survival
por: Rivinius, Rasmus, et al.
Publicado: (2018)

Elevated pre‐transplant pulmonary vascular resistance is associated with early post‐transplant atrial fibrillation and mortality
por: Rivinius, Rasmus, et al.
Publicado: (2020)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants
por: Cullell, Natalia, et al.
Publicado: (2018)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Warfarin or non-Vitamin K antagonist oral anticoagulants: Navigating the choice of oral anticoagulant drugs in the COVID-19 pandemic era
por: Heng, Cai, et al.
Publicado: (2020)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
por: Malagù, Michele, et al.
Publicado: (2023)

Comparison of Early Complications of Oral Anticoagulants after Totally Thoracoscopic Ablation: Warfarin versus Non-vitamin K Antagonist Oral Anticoagulants
por: Heo, MuHyung, et al.
Publicado: (2023)

Influence of Tricuspid Regurgitation After Heart Transplantation: A Single-center Experience
por: Krey, Rebecca, et al.
Publicado: (2023)

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants
por: Faraoni, David, et al.
Publicado: (2015)

Impact of Non-vitamin K Antagonist Oral Anticoagulant Withdrawal on Stroke Outcomes
por: Park, Joong Hyun, et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
por: Gremmel, Thomas, et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
por: Fanaroff, Alexander C, et al.
Publicado: (2022)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis
por: Santarpia, Giuseppe, et al.
Publicado: (2015)

Comparison of posttransplant outcomes in patients with no, acute, or chronic amiodarone use before heart transplantation
por: Rivinius, Rasmus, et al.
Publicado: (2017)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Non‐vitamin K oral anticoagulants versus vitamin K antagonists in post transcatheter aortic valve replacement patients with clinical indication for oral anticoagulation: A meta‐analysis
por: Chen, Yi‐feng, et al.
Publicado: (2022)

Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism
por: Goldstein, Patrick, et al.
Publicado: (2013)

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants
por: Patel, Raj
Publicado: (2016)

Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
por: Jacobs, M. S., et al.
Publicado: (2019)

Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus
por: Iqbal, Hansa, et al.
Publicado: (2020)

Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe
por: Yang, Hayang, et al.
Publicado: (2019)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants post-kidney transplantation
por: Bukhari, Muhammad A, et al.
Publicado: (2019)

Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists
por: Fedorov, Kateryna, et al.
Publicado: (2021)

Assessment of non‐vitamin K antagonist oral anticoagulants for the management of left ventricular thrombus
por: Li, Shunhui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vb9iabm49a4gmitborith1mk2s